PD-1 inhibitor （Pembrolizumab, 2mg/kg weight, once per 4 weeks and 3 times of medication usage）treatment on AIDS patients with progressive multifocal leukoencephalopathy.
This is a one-center, single-arm and prospective study, planing recruiting 10 AIDS-associated PML patients. All patients will receive PD-1 inhibitor (Pembrolizumab) for 12 weeks, and the dose for each time is 2 mg per kg/weight, and the frequency is once per 4 weeks. The effect and safety of Pembrolizumab on AIDS-associated PML will be evaluated.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Monthly usage of Pembrolizumab (2mg/kg weight) for 3 months.
the first affiliated hospital of Zhejiang university school of medicine
Hangzhou, Zhejiang, China
RECRUITINGthe rate of non-progressors and recovers of AIDS patients with PML in 6 months after receiving PD-1 inhibitor
With treatment of Pembrolizumab for 6 months, we will evaluate the rate of non-progressors and recovers of AIDS patients with PML
Time frame: 6 months
the rate of non-progressors and recovers of AIDS patients with PML in 12 months after receiving PD-1 inhibitor
With treatment of Pembrolizumab for 12 months, we will evaluate the rate of non-progressors and recovers of AIDS patients with PML
Time frame: 12 months
the negative conversion rate of John Cunningham virus (JCV) in cerebrospinal fluid，blood and urine in patients receiving Pembrolizumab.
With treatment of Pembrolizumab for 3 months, we will evaluate the negative conversion rate of JCV in cerebrospinal fluid，blood and urine
Time frame: 3 months
Side effects associated with Pembrolizumab
To investigate the safety of Pembrolizumab in HIV patients
Time frame: 12 months
The rate of patients with decreased HIV viral reservoir
To investigate the rate of patients with decreased HIV viral reservoir
Time frame: 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.